Werewolf Therapeutics (NASDAQ:HOWL) Releases Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Werewolf Therapeutics (NASDAQ:HOWL) announced its quarterly earnings data on Friday. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.02, FiscalAI reports.

Werewolf Therapeutics Trading Up 0.0%

Werewolf Therapeutics stock traded up $0.00 during midday trading on Friday, reaching $0.98. The stock had a trading volume of 317,383 shares, compared to its average volume of 296,183. The company has a fifty day moving average price of $0.98 and a two-hundred day moving average price of $0.70. Werewolf Therapeutics has a 12 month low of $0.27 and a 12 month high of $1.20. The company has a market capitalization of $47.64 million, a P/E ratio of -1.29 and a beta of 0.55.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on HOWL shares. Weiss Ratings upgraded shares of Werewolf Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 10th. Wall Street Zen raised shares of Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 22nd. Finally, Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 3rd. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $4.00.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc. is a clinical-stage biotechnology company developing medicines for cancer. Its research focuses on cytokines, immune-signaling proteins that can stimulate the body’s immune response against tumors. The company’s INDUKINE platform is designed to keep cytokine therapies inactive until they reach the tumor environment, with the goal of limiting effects on healthy tissue. Its investigational programs include WTX-124, based on interleukin-2, and WTX-330, based on interleukin-12.